Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Canadian Journal of Gastroenterology & Hepatology
Xiaoli FanLi Yang

Abstract

To explore the efficacy and safety of immunosuppressive therapy for the treatment of primary biliary cirrhosis-autoimmune hepatitis (PBC-AIH) overlap syndrome accompanied by decompensated cirrhosis. A cohort study was performed to evaluate the usefulness of immunosuppressive therapy in this unique group. This cohort study was performed between October 2013 and June 2017 and included 28 biopsy-proven patients diagnosed according to the Paris criteria. The therapies included ursodeoxycholic acid (UDCA) alone (N=14) or in combination with immunosuppression (IS) therapy (N=14). The primary endpoints were biochemical remission, liver-related adverse events, transplant-free survival, and drug side-effects. The frequency of biochemical remission for the AIH features was significantly higher in the UDCA+IS group than in the UDCA-only group (60.0 versus 9.1%, P=0.024) after 12 months of therapy but not after 3 and 6 months (28.6 versus 0%, P=0.165; 35.7 versus 7.1%, P=0.098). The rates of liver-related adverse events were lower in the combined group (2/14 versus 9/14, P=0.018). The Kaplan-Meier estimate showed that the transplant-free survival was distinct between the two groups (P=0.019). In the UDCA+IS group, mild and transient leukop...Continue Reading

References

Nov 1, 1991·Journal of Hepatology·P J Scheuer
Aug 8, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·O ChazouillèresR Poupon
Aug 8, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A J Czaja
Feb 5, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Supriya JoshiE Jenny Heathcote
Feb 3, 2007·Gastroentérologie Clinique Et Biologique·Alexandra HeurguéGérard Thiéfin
Mar 11, 2008·Lancet·Detlef Schuppan, Nezam H Afdhal
Jun 6, 2008·World Journal of Gastroenterology : WJG·Christian Rust, Ulrich Beuers
Jun 1, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael P MannsUNKNOWN American Association for the Study of Liver Diseases
Nov 12, 2010·Journal of Hepatology·Kirsten Muri BobergUNKNOWN International Autoimmune Hepatitis Group
Dec 21, 2010·Journal of Hepatology·Ansgar W Lohse, Giorgina Mieli-Vergani
Jan 29, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R Todd StravitzUNKNOWN Acute Liver Failure Study Group
Jun 12, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Alexander ZipprichMatthias M Dollinger
Jul 24, 2012·Alimentary Pharmacology & Therapeutics·P J Trivedi, G M Hirschfield
Oct 1, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ersan OzaslanPaolo Muratori
Mar 25, 2014·Alimentary Pharmacology & Therapeutics·G D'AmicoL Pagliaro
Oct 19, 2016·European Journal of Gastroenterology & Hepatology·Tadashi NamisakiHitoshi Yoshiji
Oct 28, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Guadalupe Garcia-TsaoJaime Bosch
Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver

❮ Previous
Next ❯

Citations

May 18, 2020·Journal of Clinical Medicine·Benjamin L FreedmanAlan Bonder

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
X-ray
PCR

Software Mentioned

SPSS

Related Concepts

Related Feeds

Autoimmune Hepatitis

Autoimmune hepatitis formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. Discover the latest research on autoimmune hepatitis here.

© 2022 Meta ULC. All rights reserved